Literature DB >> 24315818

Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/β-catenin signaling.

Fei Ma1, Jianguo Zhang1, Lei Zhong1, Lei Wang1, Yansong Liu1, Yimin Wang1, Lin Peng2, Baoliang Guo3.   

Abstract

MicroRNAs (miRNAs) are strongly implicated in many cancers, including breast cancer. Recently, microRNA-301a (miR-301a) has been proved to play a substantial role in gastric cancer, but its functions in the context of breast cancer remain unknown. Here we report that miR-301a was markedly upregulated in primary tumor samples from patients with distant metastases and pro-metastatic breast cancer cell lines. Gain-of-function and loss-of-function studies showed that ectopic overexpression of miR-301a promoted breast cancer cell migration, invasion and metastasis both in vitro and in vivo. Notably, Wnt/β-catenin signaling was hyperactivated in metastatic breast cancer cells that express miR-301a, and mediated miR-301a-induced invasion and metastasis. Furthermore, miR-301a directly targeted and suppressed PTEN, one negative regulator of the Wnt/β-catenin signaling cascade. These results demonstrate that miR-301a maintains constitutively activated Wnt/β-catenin signaling by directly targeting PTEN, which promotes breast cancer invasion and metastasis. Taken together, our findings reveal a new regulatory mechanism of miR-301a and suggest that miR-301a might be a potential target in breast cancer therapy.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; LEF; ORF; PTEN; T cell factor; TCF; UTR; Wnt/β-catenin; lymphoid enhancer factor; mir-301a; open reading frame; phosphatase and tensin homolog; untranslated region

Mesh:

Substances:

Year:  2013        PMID: 24315818     DOI: 10.1016/j.gene.2013.11.035

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  53 in total

1.  LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.

Authors:  Diana E Ramirez-Ardila; Kirsten Ruigrok-Ritstier; Jean C Helmijr; Maxime P Look; Steven van Laere; Luc Dirix; Els M J J Berns; Maurice P H M Jansen
Journal:  Mol Oncol       Date:  2016-07-25       Impact factor: 6.603

2.  Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer.

Authors:  Hong Yu; Hui Li; Hua Qian; Xia Jiao; Xiaowei Zhu; Xiaoqin Jiang; Guihong Dai; Junxing Huang
Journal:  Med Oncol       Date:  2014-10-14       Impact factor: 3.064

Review 3.  miRNA - Therapeutic tool in breast cancer? Where are we now?

Authors:  Karolina Zaleska
Journal:  Rep Pract Oncol Radiother       Date:  2014-11-26

4.  MiR-4465 directly targets PTEN to inhibit AKT/mTOR pathway-mediated autophagy.

Authors:  Zhouteng Tao; Chenxi Feng; Chenmei Mao; Jin Ren; Yusi Tai; Huijie Guo; Mei Pu; Yang Zhou; Guanghui Wang; Mei Wang
Journal:  Cell Stress Chaperones       Date:  2018-11-12       Impact factor: 3.667

5.  MicroRNA involvement in a metastatic non-functioning pituitary carcinoma.

Authors:  Zhenqing Wei; Cuiqi Zhou; Mei Liu; Yong Yao; Jian Sun; Jianqi Xiao; Wenbin Ma; Huijuan Zhu; Renzhi Wang
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

6.  miR-130a Deregulates PTEN and Stimulates Tumor Growth.

Authors:  Huijun Wei; Ri Cui; Julian Bahr; Nicola Zanesi; Zhenghua Luo; Wei Meng; Guang Liang; Carlo M Croce
Journal:  Cancer Res       Date:  2017-09-21       Impact factor: 12.701

7.  MicroRNA-137 inhibits cell migration and invasion by targeting bone morphogenetic protein-7 (BMP7) in non-small cell lung cancer cells.

Authors:  Yan-Rong Yang; Yun-Xia Li; Xin-Yuan Gao; Sha-Sha Zhao; Shu-Zhi Zang; Zhi-Qiang Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  O-GlcNAcylation stabilizes β-catenin through direct competition with phosphorylation at threonine 41.

Authors:  Stéphanie Olivier-Van Stichelen; Vanessa Dehennaut; Armelle Buzy; Jean-Luc Zachayus; Céline Guinez; Anne-Marie Mir; Ikram El Yazidi-Belkoura; Marie-Christine Copin; Didier Boureme; Denis Loyaux; Pascual Ferrara; Tony Lefebvre
Journal:  FASEB J       Date:  2014-04-17       Impact factor: 5.191

9.  Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma.

Authors:  Fengming Lan; Qin Qing; Qiang Pan; Man Hu; Huiming Yu; Xiao Yue
Journal:  Cell Oncol (Dordr)       Date:  2017-10-26       Impact factor: 6.730

Review 10.  Role of "oncogenic nexus" of CIP2A in breast oncogenesis: how does it work?

Authors:  Pradip De; Jennifer H Carlson; Brian Leyland-Jones; Nandini Dey
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.